JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Price:
1.7 HKD
-2.86%
Market Closed
Updated:
Apr 27, 2024
JW (Cayman) Therapeutics Co Ltd
Operating Income
|
JW (Cayman) Therapeutics Co Ltd
Operating Income Peer Comparison
Comparables:
6160
1801
603392
300122
300896
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Operating Income
-¥607.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Operating Income
-¥12B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Operating Income
-¥1.1B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Operating Income
¥1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Operating Income
¥9.9B
|
CAGR 3-Years
38%
|
CAGR 5-Years
46%
|
CAGR 10-Years
47%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Operating Income
¥1.4B
|
CAGR 3-Years
59%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Operating Income?
Operating Income
-607.5m
CNY
-607.5m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Operating Income amounts to -607.5m CNY.
What is JW (Cayman) Therapeutics Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-39%
-39%
Over the last year, the Operating Income growth was 13%. The average annual Operating Income growth rates for JW (Cayman) Therapeutics Co Ltd have been -8% over the past three years , -39% over the past five years .
You don't have any saved screeners yet
